CEL-SCI Receives Key Japanese Patent for Its Investigational Phase III Cancer Therapy Multikine

[Business Wire] – VIENNA, Va.–(BUSINESSWIRE)– CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Japanese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte … more

View todays social media effects on CVM

View the latest stocks trending across Twitter. Click to view dashboard